Monday, October 14, 2024
HomeLatest Pharma-NewsLupin received approval from U.S. FDA and launches Moxifloxacin Ophthalmic Solution USP...

Lupin received approval from U.S. FDA and launches Moxifloxacin Ophthalmic Solution USP 0.5%

Feb 14, 2020: Pharma major Lupin Limited announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the U.S. FDA earlier. The product would be manufactured at the Lupin’s Pithampur (Unit-II) facility in India. Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of the Moxeza® of Novartis.

It is indicated for the treatment of bacterial conjunctivitis which is caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of about USD 10 million in the U.S. (IQVIA MAT December 2019).

- Advertisement -

Lupin has 15 production facilities, seven research centres, more than 20,000 global employees, and has been widely known as a ‘ great place to work ‘ in the biotechnology & pharmaceuticals industry.
http://www.lupinpharmaceuticals.com/lupin-launches-moxifloxacin-ophthalmic-solution-usp-0-5.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular